NCT05754840RecruitingPhase 1/2
CANnabinoids in Pediatric ONCology
A Randomized, Double-Blind Tolerability Trial of Cannabinoids for Symptom Management in Children With Cancer: the CAN-PONC Trial
Source: ClinicalTrials.gov · Last updated 11 Jun 2026
Brief summary (registry, in English)
CANnabinoids in Pediatric ONCology is a randomized, double blind, adaptive clinical trial looking at the tolerability of cannabinoids in children with cancer across 3 Canadian children's hospitals.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 13 Feb 2023
- Start date
- 18 Jul 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- University of Manitoba
- Diseases
- Childhood cancers
- NCT number
- NCT05754840
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 60
- From 18 Jul 2025 to the primary completion date, 31 Dec 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in other clinical trials that prohibit the concurrent use of cannabis
- Anyone who is currently receiving cell therapies or immune checkpoint inhibitors
Other illness
- Children with a personal or family history of schizophrenia or psychotic disorders, substance use disorder or allergy to cannabinoids or cannabis
Lab values
- History of cardiovascular disease, severe hepatic or renal impairment defined by alanine transaminase (ALT)/ aspartate aminotransferase (AST) more than 5x upper limit of normal (ULN), creatinine more than 5x ULN or glomerular filtration rate (GFR less than) \<60 mL/min/1.73 m273m2, unstable/unmanaged arrhythmias, uncontrolled hypertension with blood pressure above 99th centile for age or history of myocardial infarction
Other
- Nabilone or other cannabis-based products use (including for recreational purposes) within the past 2 weeks or planned nabilone use for the duration of their enrollment in the trial. Current use/continued use of recreational cannabis, or not willing to abstain from recreational cannabis use during the trial
- Anyone who is pregnant or breast/chest-feeding throughout the duration of the study or has the intention to become pregnant within 3 months of study completion
- Unwilling or unable to use effective form of contraception and refrain from driving motorized vehicles (cars, motorcycles, boats, etc.) throughout the study period
Who the study is looking for
- Ages 4-17 years old at the time of enrollment
- Diagnosed with relapsed or refractory solid or hematologic malignancy including brain tumours
- Currently receiving active cancer treatment or supportive and palliative care
- Estimated survival of at least 4 months at the time of enrollment
Age in the registry: 4 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IWK Health Centre Coordinator of this site? Confirm its status | Halifax | Canada | Recruiting |
| The Hospital for Sick Children Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
| BC Children ' s Hospital Coordinator of this site? Confirm its status | Vancouver | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.